Skip NavigationSkip to Content
Return Return to Search Results

Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial

  1. Author:
    Friedman-Klabanoff, DeAnna J
    Birkhold, Megan
    Short, Mara T
    Wilson, Timothy R
    Meneses, Claudio R
    Lacsina, Joshua R
    Oliveira, Fabiano
    Kamhawi, Shaden
    Valenzuela, Jesus G
    Hunsberger, Sally
    Mateja,Allyson
    Stoloff, Gregory
    Pleguezuelos, Olga
    Memoli, Matthew J
    Laurens, Matthew B

  2. Author Address

    Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA., Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA., Biostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA., Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., PepTcell (t/a SEEK), London, United Kingdom., ConserV Bioscience, Oxfordshire, United Kingdom., Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: mlaurens@som.umaryland.edu.,
    1. Year: 2022
    2. Date: Nov 24
    3. Epub Date: 2022 11 24
  2. Journal: EBioMedicine
    1. 86
    2. Pages: 104375
  4. Type of Article: Article
  5. Article Number: 104375
  1. Abstract:

    Immunity to mosquito salivary proteins could provide protection against multiple mosquito-borne diseases and significantly impact public health. We evaluated the safety and immunogenicity of AGS-v PLUS, a mosquito salivary peptide vaccine, in healthy adults 18-50 years old. We conducted a randomized, double-blind, placebo-controlled Phase 1 study of AGS-v PLUS administered subcutaneously on Days 1 and 22 at the Center for Vaccine Development and Global Health, Baltimore, MD, USA. Participants were block randomized 1:1:1:1:1 to two doses saline placebo, two doses AGS-v PLUS, AGS-v PLUS/ISA-51 and saline placebo, two doses AGS-v PLUS/ISA-51, or two doses AGS-v PLUS/Alhydrogel. Primary endpoints were safety (all participants receiving =1 injection) and antibody and cytokine responses (all participants with day 43 samples), analysed by intention to treat. Between 26 August 2019 and 25 February 2020, 51 participants were enrolled and randomized, 11 into the single dose AGS-v PLUS/ISA-51 group and ten in other groups. Due to COVID-19, 15 participants did not return for day 43 samplings. Participants experienced no treatment-emergent or serious adverse events. All solicited symptoms in 2/10 placebo recipients and 22/41 AGS-v PLUS recipients after dose one and 1/10 placebo recipients and 22/41 AGS-v PLUS recipients after dose two were mild/moderate except for one severe fever the day after vaccination (placebo group). Only injection site pain was more common in vaccine groups (15/51 after dose 1 and 11/51 after dose 2) versus placebo. Compared to placebo, all vaccine groups had significantly greater fold change in anti-AGS-v PLUS IgG and IFN-gamma from baseline. AGS-v PLUS had favourable safety profile and induced robust immune responses. Next steps will determine if findings translate into clinical efficacy against mosquito-borne diseases. UK Department of Health and Social Care. Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.ebiom.2022.104375
  3. PMID: 36436281
  4. PMCID: PMC9700263
  5. View record in Web of Science®
  6. WOS: 000920171000007
  7. PII : S2352-3964(22)00557-6

Library Notes

  1. Fiscal Year: FY2022-2023
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel